Last Friday, Immuron’s price was $4.4727. Since then, however, it constantly collapsed and today is at $3.5600, resulting in a 20% loss in a week. But Immuron’s pre-market is rising by almost 14% amid its pleased to inform shareholders of a recent publication describing the potential antiviral benefits of IMM-124E in a mouse model and a human clinical trial.
Moreover, IMM124E, the company’s patented product, is used to produce flagship commercially available and over-the-counter supplements for gastrointestinal and digestive system immunity Immuron Travelan and Protectyn. The studies were conducted independently by Hadassah Medical Center, Jerusalem, Israel.
The company is focusing on the antivirus activity of IMM-124E, and these recently published results support the current research and development program. Immuron previously reported on studies of IMM-124E that demonstrated neutralizing activity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19 (ASX Announcements dated May 13, 2021, December 15, 2020, and July 21, 2020). The company is also pleased to report that it has filed a Patent Cooperation Treaty (PCT) application to seek patent protection internationally for IMM-124E.